Incretin-based therapies: A new potential treatment approach to overcome clinical inertia in type 2 diabetes

Acta Biomedica de l'Ateneo Parmense

Volumn 79, Issue 3, 2008, Pages 184-191

  Nicolucci, Antonio ^a   Rossi, Maria Chiara ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

Clinical inertia; Incretins; Type 2 diabetes

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; INSULIN DETEMIR; LIRAGLUTIDE; METFORMIN; MITIGLINIDE; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TESAVEL; UNCLASSIFIED DRUG; VILDAGLIPTIN; XELEVIA; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INCRETIN; NITRILE; PEPTIDE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VENOM;

ACUTE HEMORRHAGIC PANCREATITIS; ADD ON THERAPY; BODY WEIGHT; CELL FUNCTION; DIARRHEA; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEALTH CARE SYSTEM; HEALTH PERSONNEL ATTITUDE; HEMORRHAGIC PANCREATITIS; HORMONAL THERAPY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIFESTYLE; METABOLIC REGULATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SATIETY; SIDE EFFECT; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; NITRILES; PEPTIDES; PYRAZINES; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES; VENOMS;

EID: 63049108672     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Rossi MC, Nicolucci A, Arcangeli A, Cimino A, De Bigontina G, Giorda C, Meloncelli I, Pellegrini F, Valentini U, Vespasiani G; on behalf of the AMD Annals Study Group. Baseline quality of care data from a quality improvement program implemented by a network of diabetes outpatient clinics. Diabetes Care 2008 (in press).
2. Grant R, Adams AS, Trinacty CM, Zhang F, Kleinman K, Soumerai SB, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007; 30: 807-812 (Pubitemid 46556571)
3. Ziemer DC, Miller CD, Rhee MK, Doyle JP,Watkins C Jr, Cook CB, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005; 31: 564-571 (Pubitemid 41187205)
4. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005; 28: 600-606
5. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540 (Pubitemid 38857422)
6. Knecht LA, Gauthier SM, Castro JC, Schmidt RE, Whitaker MD, Zimmerman RS, et al. Diabetes care in the hospital: is there clinical inertia? J Hosp Med 2006; 1: 151-160
7. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med 2001; 135: 825-834 (Pubitemid 33051266)
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008 (in press)
9. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the "metabolic memory", the new challenge of diabetes. Diabet Med 2007; 24: 582-586
10. Triplitt C, McGill JB, Porte D Jr, Conner CS. The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. J Manag Care Pharm 2007;13: S2-16.
11. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25: 245-254
12. UK Hypoglycaemia Study Group. Examining hypoglycaemic risk in diabetes: effect of treatment and type of diabetes. Diabetologia 2007; 50: 1140-1147
13. Leese GP,Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population- based study of health service resource use. Diabetes Care 2003; 26: 1176-1180
14. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
15. Studio VADT (Veterans Affairs Diabetes Trial). Press release: http://www.diabetes.org/for-media/pr-intense-blood -glucose-control-yields-no- significant-effect-on-cvdreduction. jsp
16. Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007; 23: 1493-1507 (Pubitemid 47122158)
17. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al; The International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28: 2673-2679
18. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274 (Pubitemid 44125921)
19. Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004; 66: 193-201. (Pubitemid 39469347)
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
21. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289 (Pubitemid 41416583)
22. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443
23. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105
24. Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705 (Pubitemid 46048557)
25. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol 2008; 158: 773-784
26. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-1119 (Pubitemid 34985287)
27. Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes Systematic Review and Meta-analysis. JAMA 2007; 298: 194-206. (Pubitemid 47057766)
28. U.S. Food and Drug Administration. Information for healthcare professionals. Exenatide (Byetta). Available at the website http://www.fda.gov/ cder/drug/InfoSheets/HCP/exenatide2008HCP.htm
29. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493 (Pubitemid 46871159)
30. Drucker DJ, Buse JB, Taylor K, Kendall B, Trautmann M, Zhuang D, et al. Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. Diabetes 2008; 57 (Suppl 1): A33.
31. Marre M, Shaw J, Brandle M,Wan Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide added to a sulphonylurea (SU) offers significantly better glycaemic control and favourable weight change compared with rosiglitazone and SU combination therapy in T2D. Diabetologia 2008; 51 (Suppl. 1): P897.
32. Hermansenn K, Nauck MA, Frid A, Shah NS, Tankova T, Mitha IH, et al. Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin. Diabetologia 2008; 51 (Suppl. 1): P895.
33. Garber A, Henry R, Ratner R, Garcia Hernandez P, Rodriguez Pattzi HM, Olvera-Alvarez I et al. Significantly better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with glimepiride: all as monotherapy in type 2 diabetes. Diabetologia 2008;51(Suppl. 1): P896.
34. Zinman B, Gerich J, Buse J, Lewin A, Schwartz SL, Raskin P, et al. Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial. Diabetologia 2008; 51 (Suppl. 1): P898.
35. Russel-Jones D, Vaag A, Schmitz O, Sethi B, Lalic NM, Antic S, et al. Significantly better glycaemic control/ weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in type 2 diabetes. Diabetologia 2008; 51 (Suppl. 1): OP148.
36. Schmitz O, Russel-Jones D, Shaw J, Brandle M, Matthews D, Frid A, et al. Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline. Diabetologia 2008; 51 (Suppl. 1): P888
37. Colagiuri S, Frid A, Zdravkovic M, Le Thi TD, Vaag A, Garber A, et al. Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes. Diabetologia 2008; 51 Suppl 1: P899.
38. Matthews DR, Marre M, Le Thi TD, Zdravkovic M, Simo R, Garber A, et al. Liraglutide, a human GLP-1 analogue, significantly improves beta-cell function in subjects with type 2 diabetes. Diabetologia 2008;51 (Suppl. 1): P892
39. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637
40. Raz I, Hanefeld M, Xu L, Caria C,Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571
41. Chia CW, Egan JM. Special Features: Incretin-Based Therapies in Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2008 (in press)